Key result
GFT505 reduced fasting glycaemia and HbA1c and improved insulin sensitivity without inducing the cardiac side-effects associated with PPARγ activation in animal models.
Why the study?
Does GFT505 improve glycemic control without adverse cardiac effects in diabetic animal models compared to PPARγ agonists?
Does GFT505 improve glycemic control without adverse cardiac effects in diabetic animal models compared to PPARγ agonists?
GFT505 provides anti-diabetic efficacy similar to PPARγ agonists without the associated adverse cardiac effects in preclinical models.
Answers are grounded in this paper and cite their sources.
May support clinical testing of GFT505 in diabetes; leaves open translation of cardiac safety to humans.
We report here the efficacy and safety of GFT505, a novel liver-targeted peroxisome proliferator-activated receptor alpha/delta (PPARα/δ) agonist, in the db/db mouse model of diabetes. Mice were treated with vehicle, GFT505, PPARγ agonist rosiglitazone or dual-PPARα/γ agonist aleglitazar for up to 8 weeks. All compounds comparably reduced fasting glycaemia and HbA1c and improved insulin sensitivity. The glucose-lowering effect of GFT505 was associated with decreased hepatic gluconeogenesis, correlating with reduced expression of gluconeogenic genes. In contrast with the PPARγ-activating drugs, treatment with GFT505 did not affect heart weight and did not increase plasma adiponectin concentrations. This absence of cardiac effects of GFT505 was confirmed after 12 months of administration in cynomolgus monkeys, by the absence of echocardiographic and histological findings. Moreover, long-term GFT505 administration to monkeys induced no change in haematological parameters or in bone marrow differential cell counts. Compared to PPARγ-activating drugs, the dual-PPARα/δ agonist GFT505 therefore shows an improved benefit/risk ratio, treating multiple features of type 2 diabetes without inducing the cardiac side-effects associated with PPARγ activation.
No takes yet. Share an insight, caveat, or question.
Hanf et al. (2014) studied diabetes. GFT505 vs. vehicle, rosiglitazone, or aleglitazar was evaluated on fasting glycaemia, HbA1c, insulin sensitivity, and cardiac effects. GFT505 reduced fasting glycaemia and HbA1c and improved insulin sensitivity without inducing the cardiac side-effects associated with PPARγ activation in animal models.
Synapse has enriched 10 related papers. Consider them for comparative context: